scholarly journals Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma​

2020 ◽  
Author(s):  
Fabio S. Aguiar ◽  
André S. Melo ◽  
Ana Maria Silva Araújo ◽  
Alexandre Pinto Cardoso ◽  
Sergio A. Lopes de Souza ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Computed Tomography ◽  
Bone Marrow ◽  
Lung Function ◽  
Severe Asthma ◽  
Mononuclear Cell ◽  
Case Series ◽  
Emission Computed Tomography ◽  
Therapeutic Effects

Abstract Background: Despite recent advances in understanding its pathophysiology and development of novel therapies, asthma remains a serious public health issue worldwide. Combination therapy with inhaled corticosteroids and long-acting β2-adrenoceptor agonists results in disease control for many patients, but those who exhibit severe asthma are often unresponsive to conventional treatment, experiencing worse quality of life, frequent exacerbations, and increasing healthcare costs. Bone marrow-derived mononuclear cell (BMMC) transplantation has been shown to reduce airway inflammation and remodeling and improve lung function in experimental models of allergic asthma. However, to date, no study has evaluated the therapeutic effects of BMMCs in patients with severe asthma. Methods: This is a case series of three patients who presented with severe asthma unresponsive to conventional therapy and omalizumab. All received a single intravenous dose of autologous BMMCs (2×107) and were periodically evaluated for 1 year after the procedure. Endpoint assessments included physical examination; quality of life questionnaires; imaging (computed tomography, single-photon emission computed tomography, and ventilation/perfusion scan); lung function tests; and a 6-min walk test.Results: All patients completed the follow-up protocol. No serious adverse events attributable to BMMC transplantation were observed during or after the procedure. Lung function remained stable throughout. A slight increase in ventilation of the right lung was observed on day 120 after BMMC transplantation in one patient. All three patients reported improvement in quality of life in the early post-procedure course. Conclusions: This paper is the first to describe the effects of BMMC therapy in patients with severe asthma, providing a basis for subsequent trials to assess efficacy.

scholarly journals Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma

2020 ◽  
Author(s):  
Fabio S. Aguiar ◽  
André S. Melo ◽  
Ana Maria Silva Araújo ◽  
Alexandre Pinto Cardoso ◽  
Sergio A. Lopes de Souza ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Computed Tomography ◽  
Bone Marrow ◽  
Lung Function ◽  
Severe Asthma ◽  
Mononuclear Cell ◽  
Photon Emission ◽  
Case Series ◽  
Emission Computed Tomography

Abstract Background: Despite recent advances in understanding its pathophysiology and development of novel therapies, asthma remains a serious public health issue worldwide. Combination therapy with inhaled corticosteroids and long-acting β2-adrenoceptor agonists results in disease control for many patients, but those who exhibit severe asthma are often unresponsive to conventional treatment, experiencing worse quality of life, frequent exacerbations, and increasing healthcare costs. Bone marrow-derived mononuclear cell (BMMC) transplantation has been shown to reduce airway inflammation and remodeling and improve lung function in experimental models of allergic asthma. Methods: This is a case series of three patients who presented severe asthma, unresponsive to conventional therapy and omalizumab. They received a single intravenous dose of autologous BMMCs (2×107) and were periodically evaluated for 1 year after the procedure. Endpoint assessments included physical examination; quality of life questionnaires; imaging (computed tomography, single-photon emission computed tomography, and ventilation/perfusion scan); lung function tests; and a 6-min walk test.Results: All patients completed the follow-up protocol. No serious adverse events attributable to BMMC transplantation were observed during or after the procedure. Lung function remained stable throughout. A slight increase in ventilation of the right lung was observed on day 120 after BMMC transplantation in one patient. All three patients reported improvement in quality of life in the early post-procedure course. Conclusions: This paper described for the first time the effects of BMMC therapy in patients with severe asthma, providing a basis for subsequent trials to assess the efficacy of this therapy.

scholarly journals Herbal MedicineCordyceps sinensisImproves Health-Related Quality of Life in Moderate-to-Severe Asthma

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Ningqun Wang ◽  
Jie Li ◽  
Xiaobo Huang ◽  
Wenqiang Chen ◽  
Yujing Chen
Keyword(s):  
Quality Of Life ◽  
Treatment Group ◽  
Lung Function ◽  
Severe Asthma ◽  
Cordyceps Sinensis ◽  
Control Group ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Moderate-to-severe asthma has a substantial impact on the health-related quality of life (HR-QOL) of the patients.Cordyceps sinensisis a traditional Chinese medicine that is evaluated clinically for the treatment of many diseases, such as chronic allograft nephropathy, diabetic kidney disease, and lung fibrosis. In order to investigate the effects ofCordyceps sinensison patients with moderate-to-severe persistent asthma, 120 subjects were randomized to receive Corbin capsule containingCordyceps sinensisfor 3 months (treatment group,n=60), whereas the control group (n=60) did not receive treatment with Corbin capsule. Inhaled corticosteroid and as-neededβ-agonists were used in the treatment of both groups. HR-QOL was measured with the Juniper’s Asthma Quality of Life Questionnaire (AQLQ). The incidence of asthma exacerbation, pulmonary function testing, and serum measurements of inflammatory mediators were also evaluated. The results showed that the treatment group indicated a significant increase in AQLQ scores and lung function compared with the control group. The expression levels of the inflammation markers IgE, ICAM-1, IL-4, and MMP-9 in the serum were decreased and IgG increased in the treatment group compared with the control group. Therefore, the conclusion was reached that a formulation ofCordyceps sinensisimproved the HR-QOL, asthma symptoms, lung function, and inflammatory profile of the patients with moderate-to-severe asthma. This trial is registered withChiCTR-IPC-16008730.

scholarly journals Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience

2021 ◽  
Vol 12 ◽  
Author(s):  
Giulia Scioscia ◽  
Giovanna Elisiana Carpagnano ◽  
Carla Maria Irene Quarato ◽  
Donato Lacedonia ◽  
Sonia Santamaria ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Function ◽  
Asthma Control ◽  
Severe Asthma ◽  
Life Experience ◽  
Real Life ◽  
Eosinophilic Inflammation ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma

Background: Severe eosinophilic asthma decreases lung function and causes worsen symptoms, often forcing recurrent maintenance corticosteroid use. The aim of our real-life study was to evaluate the effectiveness of an add-on treatment with benralizumab in patients with severe eosinophilic asthma, paying particular attention to the impact on their quality of life (QoL).Materials and methods: In this prospective study, 10 outpatients with severe eosinophilic asthma were added-on with benralizumab and followed-up in our severe asthma clinic after 12 and 24 weeks. At each patient visit, pre-bronchodilator FEV1 and inflammatory markers were recorded. Variations in asthma symptoms control and QoL perception was assessed by validated questionnaires.Results: All the subjects experienced a marked reduction of nocturnal and diurnal symptoms over time and were able to stop using OCS, as documented by the improvement in Asthma control test (ACT) and Asthma Control Questionnaire score. Similarly, we recorded a statistically significant increase in patient’s QoL perception in EQ-VAS, EQ-5D-3L and Asthma Quality of Life Questionnaire (AQLQ) assessment (p < 0.05). Simultaneously we recorded a significant reduction in eosinophilic inflammation, an improvement in pre-bronchodilator FEV1. These results appear to be in line with those already obtained in the previous randomized controlled trials (RCTs).Conclusion: Our 24-weeks real life experience supports the effectiveness of an add-on treatment with benralizumab in reducing eosinophilic inflammation and OCS-use, increasing lung function and improving control of nocturnal and diurnal symptoms, as well as restoring severe asthma patients to a better QoL.

Bronchial Thermoplasty Including the Middle Lobe Bronchus Significantly Improves Lung Function and Quality of Life in Patients Suffering from Severe Asthma

Lung ◽  
2019 ◽  
Vol 197 (4) ◽  
pp. 493-499
Author(s):  
Stephan Eisenmann ◽  
Wolfgang Schütte ◽  
Faustina Funke ◽  
Filiz Oezkan ◽  
Shaheen Islam ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Function ◽  
Severe Asthma ◽  
Middle Lobe ◽  
Lobe Bronchus ◽  
Bronchial Thermoplasty

scholarly journals Lung function, asthma symptoms, and quality of life for children in public housing in Boston: a case-series analysis

2004 ◽  
Vol 3 (1) ◽  
Author(s):  
Jonathan I Levy ◽  
LK Welker-Hood ◽  
Jane E Clougherty ◽  
Robin E Dodson ◽  
Suzanne Steinbach ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Function ◽  
Public Housing ◽  
Case Series ◽  
Asthma Symptoms ◽  
Series Analysis

scholarly journals Computed Tomography–Guided Percutaneous Coblation of the Thoracic Nerve Root for Treatment of Postherpetic Neuralgia

2020 ◽  
Vol 5;23 (9;5) ◽  
pp. E487-E495
Author(s):  
Jia-Xiang Ni
Keyword(s):  
Quality Of Life ◽  
Computed Tomography ◽  
Postherpetic Neuralgia ◽  
Nerve Root ◽  
Therapeutic Effects ◽  
Ct Guided ◽  
Thoracic Nerve ◽  
Long Term Study ◽  
Number Of Patients

Background: Postherpetic neuralgia (PHN) is one of the most intractable pain disorders and often does not respond to medication, physical, and interventional procedures. Coblation technology has been demonstrated to have potential for neuralgia, but there are rare reports of the efficacy and security of coblation for PHN. The thoracic segment is the most common predilection part of PHN, so we conducted this long-term study to investigate the results of coblation for the treatment of thoracic PHN. Objectives: The aim of this study was to determine the efficacy and security of computed tomography (CT)-guided coblation of the thoracic nerve root for treatment of PHN. Study Design: Self before-after controlled clinical assessment. Setting: Department of Pain Management, Xuanwu Hospital, Capital Medical University. Methods: Seventy-seven patients with thoracic PHN sustained for at least 6 months and refractory to conservative therapy were identified. Patients underwent CT-guided percutaneous coblation to ablate the thoracic nerve root for thoracic PHN. The therapeutic effects were evaluated using a Visual Analog Scale (VAS), medication doses, and pain-related quality of life (QoL) scale before coblation, and at 1 week, and at 1, 3, and 6 months after the procedure. Patients who achieved more than 50% pain relief were defined as responders. In addition, adverse effects were also recorded to investigate the security of this procedure. Results: The VAS score significantly decreased from 7.22 ± 1.15 before the coblation to 3.51 ± 1.12 (P = 0.01), 3.02 ± 1.21 (P = 0.006), 3.11 ± 2.15 (P = 0.014), and 2.98 ± 2.35 (P = 0.008) at 1 week, and at 1, 3, and 6 months after the procedure, respectively. The number of responders were 56 (77.78%), 54 (75%), 55 (76.39%), and 54 (75%) at 1 week, and at 1, 3, and 6 months after the procedure, respectively. The doses of anticonvulsants and analgesics were decreased significantly at all time points after the procedure compared with before treatment (P < 0.05). Patient responses on the Brief Pain Inventory Short Form indicated mean scores that were significantly lower than baseline across all domains of pain interference with QoL at all evaluations (P = 0.001). Most of the patients had mild numbness and it did not affect the daily activities after the procedure. No other severe adverse events occurred during or after the procedure. Limitations: A single-center study, relatively small number of patients, short duration of review of medical record, and the retrospective study. Conclusions: CT-guided percutaneous thoracic nerve root coblation is an effective and safe method for the treatment of thoracic PHN, and the procedure can also significantly improve the QoL in patients with PHN. Key words: Neuropathic pain, quality of life, radiofrequency ablation, plasma-mediated technology, numbness

Sign in / Sign up

Export Citation Format

Share Document